Evidence map›Paper›PMID 38140635›Full record

ArticleViruses2023

Virological Characteristics of Five SARS-CoV-2 Variants, Including Beta, Delta and Omicron BA.1, BA.2, BA.5.

Yan Zeng, Fei Xia, Changfu Guo, Chunxia Hu, Yuwei Li, Xiang Wang, Qin Wu, Zhuo Chen, Jia Lu, Zejun Wang

Open access · goldAbstract read
In one paragraph

Article in Viruses, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 77% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Yan ZengWuhan Institute of Biological Products Co., Ltd., Wuhan 430207, China.ORCID 0000-0002-6263-5090
Fei XiaWuhan Institute of Biological Products Co., Ltd., Wuhan 430207, China.
Changfu GuoWuhan Institute of Biological Products Co., Ltd., Wuhan 430207, China.
Chunxia HuWuhan Institute of Biological Products Co., Ltd., Wuhan 430207, China.
Yuwei LiWuhan Institute of Biological Products Co., Ltd., Wuhan 430207, China.
Xiang WangWuhan Institute of Biological Products Co., Ltd., Wuhan 430207, China.
Qin WuWuhan Institute of Biological Products Co., Ltd., Wuhan 430207, China.
Zhuo ChenWuhan Institute of Biological Products Co., Ltd., Wuhan 430207, China.
Jia LuWuhan Institute of Biological Products Co., Ltd., Wuhan 430207, China.
Zejun WangWuhan Institute of Biological Products Co., Ltd., Wuhan 430207, China.ORCID 0000-0001-5076-3215
Wuhan Institute of Bioengineering · CN

Funding

Basic strengthening plan for key basic research projects 2023-173ZD-124National Key Research and Development Program of China 2021YFC2600200.Wuhan city major special technical research projects 2022023702025187
6 · The paper itself

Abstract

SARS-CoV-2 variants of concern (VOCs) show increasing transmissibility and infectivity and induce substantial injuries to human health and the ecology. Therefore, it is vital to understand the related features for controlling infection. In this study, SARS-CoV-2 WIV04 (prototype) and five VOCs (Beta, Delta, Omicron BA.1, BA.2 and BA.5 variants) were inoculated in Vero cells to observe their growth activities. Apart from evaluating the environmental stability at different temperatures, residual virus titers and infectivity at different temperatures (4 °C, room temperature (RT) and 37 °C) were measured over 7 days. The experiment also assessed the infectivity for different incubation durations. The growth capacity assay suggested that the WIV04, Beta and Delta variants replicated efficiently in Vero cells compared with Omicron Variants, and BA.2 replicated more efficiently in Vero cells than BA.1 and BA.5. In addition, all variants exhibited longer survivals at 4 °C and could remain infectious after 7 days, compared to RT' survival after 5 days and at 37 °C after 1 day. The virus infection assay indicated that the Omicron variant had a weaker ability to infect cells compared to the WIV04, Beta and Delta strains, and a longer infection time was required for these strains, except for BA.2.

Indexed as

COVID-19AnimalsBiological AssayChlorocebus aethiopsHumansSARS-CoV-2Vero CellsBA.2BA.5growth capacityinfectivityOmciron BA.1SARS-CoV-2stabilityvariants

Identifiers

PMID38140635
PMCPMC10747097
OpenAlexW4389481094

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.